{
  "attach_pages": "11",
  "attach_size": "1380",
  "attach_type": "0",
  "attach_url": "https://pdf.dfcfw.com/pdf/H3_AP201903071303691298_1.pdf?1551978068000.pdf",
  "company_code": "80045894",
  "eitime": "2019-03-07 17:01:27",
  "extend": {},
  "info_code": "AP201903071303691298",
  "language": "0",
  "notice_date": "2019-03-07 00:00:00",
  "notice_title": "长春高新2018年年报暨发行股份及可转债购买资产预案点评：生长激素业务经营超预期，收购金赛药业30%少数股权值得期待",
  "page_size": 1,
  "page_size_ch": 0,
  "page_size_cht": 0,
  "page_size_en": 0,
  "rating": "CCC",
  "researcher": "崔文亮",
  "security": [
    {
      "market_uni": "0",
      "publish_relation": [
        {
          "originalCode": "1044",
          "publishName": "生物制品"
        }
      ],
      "short_name": "长春高新",
      "short_name_ch": "长春高新",
      "short_name_cht": "長春高新",
      "short_name_en": "CCHN",
      "stock": "000661"
    }
  ],
  "short_name": "长春高新",
  "source_sample_name": "诚通证券",
  "star": "4"
}